DGr Pharma Acquired by Symeres
We are delighted to announce the acquisition of DGr Pharma, by Symeres, a mid-sized, transatlantic contract research and development organisation (CRO/CDMO) specialising in small-molecule drug discovery and development.
With headquarters in the Netherlands and operations across Europe and the United States, Symeres offers over 30 years of industry experience and serves biotech and pharmaceutical clients worldwide.
Symeres provides end-to-end R&D services, bridging early discovery to clinical drug substance manufacturing. Their offering spans:
- Drug Discovery & Medicinal Chemistry
– Hit finding, lead optimisation, rapid analog synthesis, computational chemistry. - Enabling Technologies
– Biocatalysis, flow chemistry, photochemistry, PROTACs, macrocycles, and other advanced chemistry solutions. - ADME-Tox / DMPK (via Admescope)
– In vitro and in vivo pharmacokinetics, metabolism studies, permeability, and toxicology profiling. - CMC & Drug Development
– Process R&D, analytical development, formulation, solid-state chemistry, stability studies. - Manufacturing
– Non-GMP scale-up for IND-enabling studies and GMP manufacturing for clinical supplies. - Biology & Oncology (via Oncolines)
– Cell-line panels, biomarker discovery, immuno-oncology assays.
With this acquisition, our consultancy and regulatory expertise will become part of Symeres’ integrated offering, extending support further along the development pathway. Together, we strengthen the ability to guide clients seamlessly from early discovery through development, registration, and manufacturing.
This partnership reflects a shared commitment to building a truly end-to-end service model. By combining our strengths, we will deliver even greater flexibility, scientific depth, and speed—helping clients bring high-quality medicines to patients worldwide.
We look forward to working closely with our new colleagues and building the next chapter of DGr Pharma together.